Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03277729
Title A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

B-cell lymphoma

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

Therapies

CD20 CAR T-cells + Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.